<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet title="XSL_formatting" type="text/xsl" href="/rss/nolsol.xslt"?>

 









<rss version="2.0">
	<channel>
		<title>NICE | Nice Front Page (Welcome to NICE)</title>
		<link>http://www.nice.org.uk/</link>
		<description>NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.</description>
		<language>en-gb</language>
		<copyright>Copyright (c) 2007 National Institute for Health and Clinical Excellence</copyright>
		<image>
			<title>NICE</title>
			<url>http://www.nice.org.uk/images/rss-logo.gif</url>
			<link>http://www.nice.org.uk/</link>
		</image>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=7054CD2B-19B9-E0B5-D40016D8914ED10F]]></guid>
			<title><![CDATA[NICE adds two new indications to guidance on somatropin to treat growth failure in children]]></title>
			<description><![CDATA[NICE has recommended somatropin (a synthetic form of human growth hormone) as a treatment option for children who have failed to grow normally due to a condition called short stature homeobox-containing gene (SHOX) deficiency, or who were smaller than expected at birth and whose growth has not normalised by the age of four.]]></description>
			<pubdate>18 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=7054CD2B-19B9-E0B5-D40016D8914ED10F]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/NICEtoProduceGuidanceToTackleSmoking.jsp]]></guid>
			<title><![CDATA[NICE to produce guidance to tackle smoking]]></title>
			<description><![CDATA[NICE is to produce a range of public health guidance to encourage people to give up smoking, after the Department of Health announced the latest topics to be referred to our work programme.]]></description>
			<pubdate>16 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/NICEtoProduceGuidanceToTackleSmoking.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=610D7B46-19B9-E0B5-D425ED62F861F960]]></guid>
			<title><![CDATA[NICE invites stakeholders to comment on 2011/12 Quality Outcomes Framework]]></title>
			<description><![CDATA[The National Institute for Health and Clinical Excellence (NICE) has today (Monday 15 March) opened its consultation on potential new indicators for inclusion in the 2011/12 Quality and Outcomes Framework (QOF). Stakeholders are invited to email their comments on a set of potential indicators via the NICE website. Anyone with an interest in health, including health professionals, patients, community groups and voluntary organisations, is encouraged to take part in the consultation.]]></description>
			<pubdate>15 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=610D7B46-19B9-E0B5-D425ED62F861F960]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NICEtoConsiderLatestBloodPressureResearch.jsp]]></guid>
			<title><![CDATA[NICE to consider latest blood pressure research]]></title>
			<description><![CDATA[NICE is to examine latest research suggesting that people who have fluctuating blood pressure readings could be at greater risk of suffering a stroke than those with consistently high readings.]]></description>
			<pubdate>12 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NICEtoConsiderLatestBloodPressureResearch.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=52D03842-19B9-E0B5-D42BDF53D5F4BF04]]></guid>
			<title><![CDATA[NICE draft guidance proposes treatment options for psoriatic arthritis]]></title>
			<description><![CDATA[The National Institute for Health and Clinical Excellence (NICE) has published draft guidance today (15 March) recommending etanercept (Enbrel, Wyeth Pharmaceuticals) and adalimumab (Humira, Abbott Laboratories) for the treatment of adults with active and progressive psoriatic arthritis when specific criteria are met.]]></description>
			<pubdate>15 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=52D03842-19B9-E0B5-D42BDF53D5F4BF04]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/TrustsUrgedToFollowNICEGuidance.jsp]]></guid>
			<title><![CDATA[Trusts urged to follow NICE guidance to cut health inequalities]]></title>
			<description><![CDATA[Primary care trusts (PCTs) should follow NICE public health guidance to help reduce health inequalities across England, as a report by the Audit Commission reveals a widening gap between the poor and those who are better off.]]></description>
			<pubdate>11 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/TrustsUrgedToFollowNICEGuidance.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=4C7D88F0-19B9-E0B5-D4386D476CC502A5]]></guid>
			<title><![CDATA[Childhood bedwetting: Draft guidance from NICE out today]]></title>
			<description><![CDATA[NICE is developing advice for the NHS on how to treat and look after children who wet the bed. The draft clinical guideline is available from today (11 March) for public consultation.]]></description>
			<pubdate>11 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=4C7D88F0-19B9-E0B5-D4386D476CC502A5]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=47B847D9-19B9-E0B5-D4DC59199A97EC55]]></guid>
			<title><![CDATA[NICE publishes first evidence-based draft guidelines on Barrett's oesophagus - ablative therapy]]></title>
			<description><![CDATA[NICE has today (10 March) published a draft clinical guideline on the use of ablative therapies for the treatment of Barrett's oesophagus. &nbsp;Ablative therapies destroy the abnormal cells within the oesophagus caused by the condition, without removing an entire section of oesophagus. This is the first time national guidelines have considered the use of these therapies to treat Barrett's oesophagus, and NICE is now opening a consultation on the draft recommendations.]]></description>
			<pubdate>10 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=47B847D9-19B9-E0B5-D4DC59199A97EC55]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/CampaignToImproveAccessToTalkingTherapies.jsp]]></guid>
			<title><![CDATA[Campaign launched to improve access to NICE-approved talking therapies]]></title>
			<description><![CDATA[The mental health charity Mind has teamed up with the Royal College of General Practitioners (RCGP) and the Royal College of Psychiatrists to launch a new campaign calling for better access to psychological therapies.]]></description>
			<pubdate>9 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/CampaignToImproveAccessToTalkingTherapies.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NICEEducationModulesARealHitWithUsers.jsp]]></guid>
			<title><![CDATA[NICE education modules &quot;a real hit&quot; with users]]></title>
			<description><![CDATA[Over 95,000 healthcare professionals have used NICE's online learning modules to improve their knowledge of key clinical areas since their launch in 2005.]]></description>
			<pubdate>8 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NICEEducationModulesARealHitWithUsers.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NICErecommendsDrugForMostCommonFormOfLeukaemia.jsp]]></guid>
			<title><![CDATA[NICE recommends drug for most common form of leukaemia]]></title>
			<description><![CDATA[NICE has today recommended the use of rituximab (MabThera) as a treatment for some patients who suffer from relapsed or refractory chronic lymphocytic leukaemia, the most common form of the cancer in the UK.]]></description>
			<pubdate>4 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NICErecommendsDrugForMostCommonFormOfLeukaemia.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NICEUnableToRecommendBoneMarrowDiseaseDrug.jsp]]></guid>
			<title><![CDATA[NICE unable to recommend bone marrow disease drug]]></title>
			<description><![CDATA[NICE is disappointed to be unable to recommend the use of azacitidine (Vidaza) for the treatment of myelodysplastic syndromes (MDS), a group of rare bone marrow disorders.]]></description>
			<pubdate>4 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NICEUnableToRecommendBoneMarrowDiseaseDrug.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=28CBE098-19B9-E0B5-D4549A3B86234D20]]></guid>
			<title><![CDATA[Draft guidance from NICE hopes to help people with motor neurone disease breathe more easily]]></title>
			<description><![CDATA[The National Institute for Health and Clinical Excellence (NICE) is currently developing guidance for the NHS on the use of non-invasive mechanical ventilation for people with motor neurone disease. The draft recommendations are now available on the NICE website for public consultation.]]></description>
			<pubdate>4 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=28CBE098-19B9-E0B5-D4549A3B86234D20]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=24D6E2BC-19B9-E0B5-D45414094C562E73]]></guid>
			<title><![CDATA[NICE recommends infliximab and adalimumab for the treatment of severe, active Crohn's disease]]></title>
			<description><![CDATA[In final draft guidance published today (4 March) NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn's disease whose condition has not responded to conventional therapy, or who are intolerant of or have contraindications to conventional therapy.]]></description>
			<pubdate>4 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=24D6E2BC-19B9-E0B5-D45414094C562E73]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=24E41D58-19B9-E0B5-D4E29B1A9A6C7F33]]></guid>
			<title><![CDATA[NICE set to recommend rituximab for relapsed or refractory chronic lymphocytic leukaemia]]></title>
			<description><![CDATA[The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab (MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia.]]></description>
			<pubdate>4 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=24E41D58-19B9-E0B5-D4E29B1A9A6C7F33]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=24CE647D-19B9-E0B5-D481A7CAF01F8FD6]]></guid>
			<title><![CDATA[NICE asks for more data on new drug for rheumatoid arthritis]]></title>
			<description><![CDATA[NICE's independent appraisal committee has asked the manufacturer of tocilizumab (RoActemra), a new treatment for moderate to severe active rheumatoid arthritis, for further additional information on its product.]]></description>
			<pubdate>4 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=24CE647D-19B9-E0B5-D481A7CAF01F8FD6]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=242DB598-19B9-E0B5-D4AD9538B786739D]]></guid>
			<title><![CDATA[NICE appraisal of azacitidine for myelodysplastic syndromes]]></title>
			<description><![CDATA[The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of azacitidine (Vidaza, Celgene) for myelodysplastic syndromes. In the final draft guidance, published today (4 March 2010).]]></description>
			<pubdate>4 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=242DB598-19B9-E0B5-D4AD9538B786739D]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NICEtoPlayKeyRoleInNationalAutismStrategy.jsp]]></guid>
			<title><![CDATA[NICE to play key role in national autism strategy]]></title>
			<description><![CDATA[NICE is developing a clinical guideline to help improve the care of adults with autism that will contribute to achieving the aims of the first ever autism strategy for adults in England.]]></description>
			<pubdate>3 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NICEtoPlayKeyRoleInNationalAutismStrategy.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=237624B6-19B9-E0B5-D451499675639844]]></guid>
			<title><![CDATA[NICE consults on draft recommendations for treating rheumatoid arthritis after treatment with a TNF inhibitor has failed]]></title>
			<description><![CDATA[NICE is currently appraising a number of drugs as possible treatments for rheumatoid arthritis after treatment with a tumour necrosis factor (TNF) inhibitor has failed. &nbsp;This is a part review of NICE technology appraisal guidance 36, and a review of NICE technology appraisal guidance 126 and 141. NICE has put its initial draft guidance on the NICE website, and this is now open for public consultation.]]></description>
			<pubdate>3 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=237624B6-19B9-E0B5-D451499675639844]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=FF6B826F-19B9-E0B5-D454CF529FE62CD6]]></guid>
			<title><![CDATA[New NICE guidance on school-based methods to prevent children and young people smoking]]></title>
			<description><![CDATA[Public health guidance from the National Institute for Health and Clinical Excellence (NICE) published today (Wednesday 24 February) focuses specifically on school-based methods to prevent children and young people from starting to smoke.]]></description>
			<pubdate>24 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=FF6B826F-19B9-E0B5-D454CF529FE62CD6]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=FBBC6BA2-19B9-E0B5-D489E7A4BAA77386]]></guid>
			<title><![CDATA[New NICE guidance set to help people with rheumatoid arthritis]]></title>
			<description><![CDATA[Final guidance published today (Wednesday 24 February 2010) by the National Institute for Health and Clinical Excellence (NICE) means that another drug &nbsp;- certolizumab pegol (Cimzia) &nbsp;- can be considered for some people in England and Wales suffering with rheumatoid arthritis.]]></description>
			<pubdate>24 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=FBBC6BA2-19B9-E0B5-D489E7A4BAA77386]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NICERecommendsDrugForSoftTissueCancers.jsp]]></guid>
			<title><![CDATA[NICE recommends drug for soft tissue cancers]]></title>
			<description><![CDATA[NICE has today recommended the use of trabectedin (Yondelis) on the NHS, in a move that could help to extend the lives of hundreds of patients with advanced soft tissue sarcoma.]]></description>
			<pubdate>24 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NICERecommendsDrugForSoftTissueCancers.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/NICEIssuesGuidanceToPromoteSafetyStandardsForDonorBreastMilk.jsp]]></guid>
			<title><![CDATA[NICE issues guidance to promote safety standards for donor breast milk]]></title>
			<description><![CDATA[NICE has published a clinical guideline on donor milk banks to provide recommendations on the safe and effective operation of such services, and will help to ensure that good practice is consistent across the UK.]]></description>
			<pubdate>24 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/NICEIssuesGuidanceToPromoteSafetyStandardsForDonorBreastMilk.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=FA8E8DCF-19B9-E0B5-D4E5D4456F7F5C16]]></guid>
			<title><![CDATA[New NICE guideline aims to promote consistent safety standards for donor breast milk]]></title>
			<description><![CDATA[New guidance published today (24 February) by the National Institute for Health and Clinical Excellence (NICE) aims to reinforce the safety of donor breast milk by making recommendations to maintain high standards of practice in specialist milk banks in the UK.]]></description>
			<pubdate>24 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=FA8E8DCF-19B9-E0B5-D4E5D4456F7F5C16]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=FB4AA582-19B9-E0B5-D497E414F85E155B]]></guid>
			<title><![CDATA[NICE instructs NHS on new drug for advanced soft tissue sarcoma]]></title>
			<description><![CDATA[New guidance published today (24 February) by the National Institute for Health and Clinical Excellence (NICE) will give a specific group of cancer patients access to a new drug on the NHS which could help extend their lives.]]></description>
			<pubdate>24 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=FB4AA582-19B9-E0B5-D497E414F85E155B]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/PregnancyWeightGainLinkedToDiabetes.jsp]]></guid>
			<title><![CDATA[Pregnancy weight gain linked to diabetes, as NICE issues draft weight management guidance]]></title>
			<description><![CDATA[Women who put on excessive weight during pregnancy could increase their risk of developing diabetes during the second and third trimester by 74 per cent, according to US research.]]></description>
			<pubdate>23 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/PregnancyWeightGainLinkedToDiabetes.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/LookedAfterGuidanceToImproveQualityofLife.jsp]]></guid>
			<title><![CDATA[Looked-after guidance to improve quality of life for children and young people]]></title>
			<description><![CDATA[NICE and SCIE (the Social Care Institute for Excellence) have now issued joint draft guidance to improve the quality of life for looked-after children and young people.]]></description>
			<pubdate>16 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/LookedAfterGuidanceToImproveQualityofLife.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NICEDementiaGuidelinesNotFollowedReportFinds.jsp]]></guid>
			<title><![CDATA[NICE dementia guidelines not followed, report finds]]></title>
			<description><![CDATA[Dementia services in England are not getting the priority that they deserve, with many trusts failing to follow recommendations set out in NICE dementia guidelines, a report by the National Audit Office has found.]]></description>
			<pubdate>14 Jan 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NICEDementiaGuidelinesNotFollowedReportFinds.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=270F36EE-19B9-E0B5-D4ACAB95EAF9B93C]]></guid>
			<title><![CDATA[NICE to publish final guidance on topotecan for the treatment of small-cell lung cancer and preliminary recommendations for bevacizumab for metastatic colorectal cancer]]></title>
			<description><![CDATA[Final guidance published on 25 November recommends topotecan as a second line treatment for relapsed lung cancer, and preliminary recommendations published for consultation on 24 November state that bevacizumab for the treatment of metastatic colorectal cancer does not represent a cost-effective use of NHS resources.]]></description>
			<pubdate>24 Nov 2009, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=270F36EE-19B9-E0B5-D4ACAB95EAF9B93C]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/newsarchive/2009/howniceguidanceishelpingthenhsthroughfinancialuncertainty.jsp]]></guid>
			<title><![CDATA[How NICE guidance is helping the NHS through financial uncertainty]]></title>
			<description><![CDATA[With the current financial situation in the UK set to result in challenging times for the NHS, the role of NICE will become ever more important. As NHS service providers look to balance budgets, NICE guidance will continue to play its part through ensuring quality care for patients whilst making sure service providers are aware of how they can best spend their limited resources.]]></description>
			<pubdate>15 Nov 2009, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/newsarchive/2009/howniceguidanceishelpingthenhsthroughfinancialuncertainty.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/CitizensCouncilReport.jsp]]></guid>
			<title><![CDATA[Feature: Departing from the threshold]]></title>
			<description><![CDATA[Are there circumstances where NICE should recommend treatments we would not normally consider cost effective? Our Citizens Council considered the issue, and presented its report at the NICE Board meeting on 22 May.]]></description>
			<pubdate>3 Jun 2009, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/CitizensCouncilReport.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/nicepressoffice/nice_press_office.jsp]]></guid>
			<title><![CDATA[There are no upcoming press events]]></title>
			<description><![CDATA[The next NICE press event will be publicised on this page. Please contact the NICE press team on 0845 003 7782 if you have any enquiries about future press events.]]></description>
			<pubdate>10 May 2009, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/nicepressoffice/nice_press_office.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/NICETenYearsOn.jsp]]></guid>
			<title><![CDATA[NICE 10 years on]]></title>
			<description><![CDATA[The National Institute for Health and Clinical Excellence (NICE) is 10 years old. Since its inception, NICE has frequently hit the headlines, and is now a familiar name to most people across the UK. But why was NICE established, and how has it grown and changed in the last decade?]]></description>
			<pubdate>28 Apr 2009, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/NICETenYearsOn.jsp]]></link>
			
			
			
		</item>
		
	</channel>
</rss>